Pregled bibliografske jedinice broj: 738061
Visfatin is not associated with inflammatory markers in patients on hemodialysis
Visfatin is not associated with inflammatory markers in patients on hemodialysis // Biochemia Medica / Šimundić, Ana-Maria (ur.).
Zagreb: Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2012. str. A188-A188 (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 738061 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Visfatin is not associated with inflammatory markers in patients on hemodialysis
Autori
Ćelap, Ivana ; Šimundić, Ana-Maria ; Nikolac, Nora ; Miler, Marijana ; Altabas, Karmela ; Šefer, Siniša
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Biochemia Medica
/ Šimundić, Ana-Maria - Zagreb : Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2012, A188-A188
Skup
2nd European Joint Congress of EFLM and UEMS and 7th Congress of the Croatian Society for Medical Biochemistry and Laboratory medicine (CSMBLM): Laboratory Medicine at the Clinical Interface
Mjesto i datum
Dubrovnik, Hrvatska, 10.10.2012. - 13.10.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
chronic renal disease; inflamation; visfatin
Sažetak
Patients with chronic renal disease often suffer from diverse cardiovascular complications. Endothelial dysfunction has been involved in development of different forms of the cardiovascular diseases, including chronic renal disease. In recent years, ubiquitous adipokine called visfatin has been considered as a novel marker of endothelial dysfunction and inflammation. Thus, the aim of our study was to investigate the association of serum visfatin concentrations and well-established markers of cardiovascular risk in the patients on hemodialysis. Serum and plasma samples from 66 patients (40 males and 26 females) treated by hemodialysis were analysed for visfatin, fibrinogen, CRP and PAI-1 levels. Visfatin was determined by ELISA method while CRP, fibrinogen and PAI-1 were obtained by standard laboratory methods. Visfatin did not correlate with the studied markers of inflammation (CRP (r =-0.05, P = 0.152) ; PAI-1 (r = -0.08, P = 0.558) and fibrinogen (r = 0.04, P = 0.772)). Statistically significant correlation between visfatin level and fibrinogen (r = 0.51 ; P = 0.008) and the time on dialysis (r = 0.70 ; P < 0.001) was observed in female patients. In conclusion, visfatin is not associated with CRP, fibrinogen and PAI-1 in patients on hemodialysis.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Šimundić, Ana-Maria, MZOS ) ( CroRIS)
Ustanove:
KBC "Sestre Milosrdnice"
Profili:
Ana-Maria Šimundić
(autor)
Nora Nikolac
(autor)
Marijana Miler
(autor)
Karmela Altabas
(autor)
Ivana Ćelap
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE